Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consort, West Pharma Exubera alliance

This article was originally published in Clinica

Executive Summary

Consort Medical and West Pharmaceutical Services have ended their respective manufacturing and supply deals with Nektar Therapeutics for the Exubera insulin inhaler. Consort is set to receive £11m ($21.6m) from Nektar, while West Pharma did not disclose the amount that it would receive. San Carlos, California-based Nektar is required to pay Consort for reimbursement of costs and expenses under the terms of the original agreement, while West Pharma said that it would be reimbursed for facility, inventory, raw materials and personnel costs. Nektar holds the intellectual property to Exubera and the original agreement saw Consort (Milton Keynes, UK) and West Pharma (Lionville, Pennsylvania) manufacture the device. Manufacturing of the technology was ceased last October by Pfizer (who produced the insulin used in the devices) due to poor sales of the device. Analysts predicted last November that it would be Nektar, rather than Consort, West Pharma or Pfizer that would bear the brunt of the financial fallout from the ailing sales (see Clinica No 1279, p 12).

You may also be interested in...

Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s

Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.

ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts